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Abstract
Alcohol misuse is a ravaging public health and social problem. Its harm can affect the drinkers and the whole society.
Alcohol-dependence is a phase of alcohol misuse in which the drinker consumes excessive amounts of alcohol and has a
continuous urge to consume alcohol. Current methods of alcohol dependence diagnoses are questionnaires and some bio-
markers. However, both methods lack specificity and sensitivity. Metabolomics is a scientific field which deals with the identi-
fication and the quantification of the metabolites present in the metabolome using spectroscopic techniques such as nuclear
magnetic resonance (NMR). Metabolomics helps to indicate the perturbation in the levels of metabolites in cells and tissues
due to diseases or ingestion of any substances. NMR is one of the most widely used spectroscopic techniques in metabolo-
mics because of its reproducibility and speed. Some recent metabolomics studies were conducted on alcohol consumption
and alcohol misuse in animals and humans. However, few focused on identifying alcohol dependence novel biomarkers.
A sensitive and specific technique such as NMR based metabolomics applied to find novel biomarkers in plasma and urine
can be useful to diagnose alcohol-dependence.
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1. Introduction
Alcohol drinking is ubiquitous public health problem.
Its detrimental effect does not only ravage the consumers, but
also their families and societies. The World Health Organiza-
tion (WHO) reported 2.5 million death cases every year due to
the hazardous consumption of alcohol (Institute of Alcohol
Studies [IAS], 2013; World Health Organization [WHO, 2011]).
The United States reported 24,518 death cases due to alcohol
consumption in 2009, of which 15,183 of them died due to
alcoholic liver cirrhosis (National Center for Health Statis-
tics [NCHS], 2009). Studies have shown that the harmful
effects of alcohol consumption are the highest compared to
that of other illicit drugs (van Amsterdam & van den Brink,
2013).  Alcohol  intoxication  usually  leads  to  drastic  and
destructive behaviour such as accidents, injuries and crimes
which  may  create  social  problems  (Couture  et  al.,  2010;
Vaaramo, Puljula, Tetri, Juvela, & Hillbom, 2012). A growing
body of literature had asserted the harmful effect of alcohol
consumption on vital organs. Although some studies advo-
cated cardio protective role of moderate alcohol consump-
tion, (Boto-Ordonez et al., 2013; Wallerath, Poleo, Li, &
Förstermann,  2003),  other  studies  contradicted  this  by
indicating that the protective role is overvalued (Fillmore,
Stockwell, Chikritzhs, Bostrom, & Kerr, 2007; Plunk, Syed-
Mohammed, Cavazos-Rehg, Bierut, & Grucza, 2013; van
Amsterdam & van den Brink, 2013). The average volume
of  alcohol  consumption  is  associated  with  liver  cirrhosis,
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depression, gastric ulcer, malabsorption, oesophageal reflux,
diarrhea and osteoporosis (Aguilera-Barreiro Mde, Rivera-
Marquez, Trujillo-Arriaga, Ruiz-Acosta, & Rodriguez-Garcia,
2013; Bujanda, 2000; Fini et al., 2012; Rehm et al., 2003).
Besides, it causes immune system impairment (Karavitis &
Kovacs, 2011). Therefore, chronic alcohol drinkers usually
are highly susceptible to acquiring fatal infections (Romeo,
Warnberg, & Marcos, 2010). Different patterns of alcohol con-
sumption are risk factors for liver cancer, breast cancer, colon
cancer, renal cell cancer and oropharyngeal cancer (Baan et
al., 2007; Bagnardi et al., 2013). A meta-analysis that aimed
to investigate the association between light alcohol drinking
and different types of cancer has concluded that light drink-
ing is associated with oropharyngeal cancer, breast cancer
and  oesophageal  cancer  (Bagnardi  et  al.,  2013).  In  other
words, chronic alcohol drinking can lead to vital organs injury
and then to subsequent failure. This requires efforts to en-
courage the avoidance of chronic alcohol drinking. The early
identification of people who might be chronic consumers of
alcohol  will  help  save  their  health  and  the  quality  of  their
lives.
2. Alcohol-dependence (AD)
The  National  Health  Committee,  Wellington-New
Zealand,  in  the  guidelines  for  recognizing,  assessing  and
treating  alcohol  and  cannabis  abuse  in  primary  care,  has
adapted a definition for alcohol dependence (AD) based on
the American Psychiatric Association’s classification system
(DSM-IV),  as  the  following:” A  maladaptive  pattern  of
alcohol use leading to clinically significant impairment or
distress” (National Health Committee, 1999). This distress has
many symptoms, such as a desire to drink more amounts of
alcohol to attain the intoxication effect, spending more time in
consuming or recovering from alcohol , refraining from social
life activities, searching for events or places that will include
drinking  alcohol,  making  ineffective  efforts  to  cut  down
alcohol  consumption  and  having  physical  disorders  after
reducing the amount of consumed alcohol such as tremors,
anxiety,  hallucination,  nausea  and  vomiting  (Best  Practice
Advocacy Centre of New Zealand, 2010).
The  data  showed  that  when  the  habit  of  drinking
alcohol starts earlier in age, the susceptibility of developing
AD is higher (Grant & Dawson, 1997). This implies that when
individuals  become  alcohol  dependent,  they  have  already
spent long period of exposure to the detrimental effects of
alcohol consumption and hence will start to suffer failure of
vital organs. Because early diagnosis of disease can lead to
early start of treatment, the early detection of AD is crucial
for preventing organs failure. For instance, the early detection
of AD might prevent the progression of liver injury due to
alcohol consumption to the irreversible phase of liver failure
in AD individuals.
3. Current Diagnostic Methods of Alcohol-dependence
Currently,  AD  questionnaires  are  the  main  clinical
methods of diagnosis in clinical practice. Some biomarkers
can  also  be  used  to  aid  the  diagnosis.  As  biomarkers  are
usually produced by the body in response to disease or organ
injury,  a  group  of  biomarkers  were  deduced  from  studies
which investigated the harmful effects of alcohol consump-
tion on body organs (Adias, Egerton, & Erhabor, 2013; Free-
man & Vrana, 2010; Kumar, 2010). Therefore, the biomarkers
of organ injury, such as liver injury, commonly used as bio-
markers of AD. However, their specificity to AD is reduced by
being biomarkers of organ injury regardless of the cause of
the  injury.  Such  biomarkers  may  lead  to  confusion  of  AD
diagnosis with other diseases, such as non-alcoholic liver
cirrhosis (Litten, Bradley, & Moss, 2010).
3.1 AD Questionnaires
Several  questionnaires  have  been  developed  to
indicate alcohol dependence diagnosis. The commonly used
questionnaires are the alcohol use disorders identification
test (AUDIT), the short version of AUDIT (AUDIT-C) and
Michigan alcoholism screening test (MAST) (Best Practice
Advocacy Centre of New Zealand, 2010). These question-
naires  consist  of  set  of  questions  that  can  differentiate
between harmful and dependent alcohol consumption, and
predict the leading risk factors of some diseases associated
with alcohol consumption.
The  main  drawback  of  AD  questionnaires  is  the
subjective nature of its measurement. They may not provide
an actual estimation of an individuals’ alcohol consumption
due to the denial and under reporting of regularly consumed
alcohol amounts. Moreover, there are limitations in the vali-
dations of these questionnaires due to the lack of standard
questionnaires  or  definite  diagnostic  tools  to  be  used  as
validation reference (Kroke et al., 2001).
3.2 Biomarkers
Biomarkers  are  biological  indicators  of  a  specific
medical  condition  or  disease,  which  can  be  tested  or
measured by using lab tools. The National Institute of Health
(NIH)  Biomarkers  Definitions  Working  Group  defined  a
biomarker as “ a characteristic that is objectively measured
and  evaluated  as  an  indicator  of  normal  biological
processes, pathogenic processes or pharmacologic responses
to a therapeutic intervention” (National Institute of Health
[NIH], 2001).
Studies that were conducted to investigate the mecha-
nisms of alcohol induced organ damage have found several
mechanisms/pathophysiology of injuries involving certain
biomarkers. Therefore, today, it is common practice to use
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blood  and  urine  biomarkers  of  organ  damage  to  diagnose
AD. For example, the raise of liver enzymes such as Alanine
Aminotransferase (ALT), Aspartate aminotransferase (AST)
and Gamma glutamyl transferase (GGT) in AD individuals is
indicator of alcohol induced liver injury (Adias et al., 2013).
The differences in the levels of AST and GGT in AD indivi-
duals compared to abstainers were found to be significant in
several studies (Adias et al., 2013; Quaye, Nyame, Dodoo,
Gyan, & Adjei, 1992). The GGT is available in cell membranes
of the tissues of some organs such as the liver, kidney, spleen,
pancreas  and  heart  (Litten  et  al.,  2010).  Chronic  alcohol
consumption results in an inflammation and necrosis of those
cells. Consequently, this might increase the leakage of GGT
from  the  destroyed  cells  (especially  hepatic  cells)  thereby
leading to an elevation in serum GGT (Litten et al., 2010;
Tavakoli, Hull, & Michael, 2011). The GGT has a long window
of  assessment.  It  remains  elevated  for  two  to  three  weeks
after alcohol cessation, and it takes two weeks to elevate after
the  relapsing  of  heavy  drinking  (Best  Practice  Advocacy
Centre  of  New  Zealand,  2010).  It  has  20%  sensitivity  and
65.2% specificity (Larkman, 2013).
Other AD biomarkers include the mean corpuscular
volume  (MCV),  carbohydrate-deficient  transferrin  (CDT),
phosphatidylethanol  (PEth),  ethyl  Glucuronide  (EtG)  and
ethyl sulfate (EtS) (Beckonert et al., 2007; Freeman & Vrana,
2010; Harrigan, Maguire, & Boros, 2008; Litten et al., 2010;
Rinck et al., 2007). The MCV which is measurement of red
blood cells size can be used as an indicator of the chronic use
of alcohol rather than the acute intake (Tavakoli et al., 2011),
as  chronic  use  increases  the  size  of  red  blood  cells  (Best
Practice Advocacy Centre of New Zealand, 2010). The level
of MCV can remain high for several months after cessation
(Litten et al., 2010). The CDT is frequently used AD bio-
marker. Transferrin is glycoprotein that is synthesized and
released by the liver which transports iron throughout the
body. Regular high alcohol intake leads to decrease in the
number  of  carbohydrate  residues  (sialic  acid)  attached  to
transferrin, thereby increasing carbohydrate deficient sites
(Best Practice Advocacy Centre of New Zealand, 2010). Serum
CDT elevates with regular and heavy drinking (60-80 g per
day) and usually returns to normal after two to three weeks
of cessation (Stibler, 1991). Because of the improvement in
CDT measurement methods, the sensitivity and specificity
of  its  testing  has  increased.  Therefore,  the  food  and  drug
administration  (FDA)  has  affirmed  CDT  as  a  biomarker  of
heavy alcohol consumption (Litten et al., 2010). The PEth is
a phospholipid formed by phospholipase D enzyme in the
presence of ethanol. It remains elevated in the blood for one
to two weeks after cessation of moderate to heavy alcohol
intake (Stewart et al., 2009). The PEth is more sensitive than
other  AD  biomarkers  as  it  is  not  affected  by  the  liver  state.
The EtG is direct metabolite of ethanol conjugation in hepatic
endoplasmic reticulum with glucuronic acid through glucu-
ronosyltransferase  enzyme.  It  can  be  measured  in  blood,
urine and hair. Urine EtG can be detected up to one to two
days after alcohol consumption which is longer than the life
span of EtG in serum. Similarly, EtS is metabolite of ethanol
conjugation with sulfur by sulfa-transferase enzyme. Both
EtG and EtS levels are positively correlated in urine samples
(Litten et al., 2010). Of further interest, the altered level of the
inflammatory mediators (cytokines) due to consumption which
is correlated with the harmful effects of alcohol on bone, lung,
liver  and  other  tissues  were  suggested  as  AD  biomarkers
(Achur, Freeman, & Vrana, 2010; Birkedal-Hansen, 1993; Fini
et al., 2012). Furthermore, as coagulating factors are being
synthesized  in  the  liver,  a  study  has  concluded  that
prothrombin time (PT) and activated partial thromboplastin
time (APTT) are significantly elevated in AD individuals and
therefore, they can be used to aid AD diagnoses (Adias et al.,
2013).
3.2.1  Limitations of current AD biomarkers
Although  most  of  current  AD  biomarkers  are
commonly used to aid in the diagnosis of AD, their accurate
productivity is limited. This is mainly due to their low specific-
ity and sensitivity, which may lead to false diagnosis. The
AST and ALT are not specific to AD; they are usually used
to screen liver damage regardless of the etiology (Adias et al.,
2013; Litten et al., 2010). Similarly, GGT can be elevated
in non-alcoholic liver disease, smoking, obesity, diabetes
mellitus, age, nutritional factors, metabolic disorders and by
some medications such as barbiturates, anticonvulsants and
anticoagulants.  The  MCV  might  be  elevated  in  folate  and
vitamin B12 deficiencies, hypothyroidism, non-alcoholic liver
disease, haemolysis, bleeding disorders and in patients whom
are on medications that can induce bone marrow disorders
(Litten et al., 2010). The EtG may indicate false positive results
if urine contains yeast as urine glucose will be converted to
alcohol  and  then  to  EtG.  This  may  be  seen  particularly  in
diabetic patients who have high levels of glucose in urine.
Moreover, the EtG’s window of assessment is between one
to two days after alcohol cessation, which is too short time
to  detect  AD.  The  PEth  has  lower  discrimination  between
moderate and heavy drinkers (Stewart et al., 2009). The CDT
sensitivity is like GGT, but with higher specificity. A recent
study to evaluate and to compare the range of AD biomarkers
of a group of heavy drinkers in Russia concluded that CDT
might be the best biomarker with 67% sensitivity and 71%
specificity to detect a daily average alcohol consumption of
40g and above (McDonald et al., 2013). However, the use of
CDT as an AD biomarker is hindered by the possibilities of
false positives due to rare genetic transferrin variants, chronic
end-stage liver disease, smoking, body weight, female gender,
primary biliary cirrhosis and hepatocarcinoma (Litten et al.,
2010).
In an approach to increase the sensitivity and speci-
ficity  of  AD  biomarkers,  some  combinations  had  been
examined. However, combination of biomarkers could limit,
but not rule out the risk of false diagnosis (Larkman, 2013).
The best suggested combination is CDT, GGT and MCV. This
combination might help in males and females, heavy drinkers
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with or without liver diseases (Litten et al., 2010). Another
combination  is  CDT  and  MCV,  which  has  been  shown  to
improve sensitivity and to perform better than either one of
the  biomarkers  alone.  However,  the  risk  of  false  diagnosis
cannot be excluded (Tavakoli et al., 2011). In general, the
questionnaires  and  current  AD  biomarkers  are  not  the
accurate methods to diagnose AD accurately. Therefore, it is
reasonable to argue that finding more objective measurement
of novel AD biomarkers would be of an advantage.
4. Systems Biology
Systems biology is a biological approach that aims to
investigate and to explore the complexity of molecular pertur-
bation by the comprehensive integration of different bio-
databases of molecular, genetic and metabolic networks, and
the individual interaction between the components of each
network  (Breitling,  2010;  Kuster,  Merkus,  van  der  Velden,
Verhoeven,  &  Duncker,  2011;  Louridas  &  Lourida,  2012;
Louridas,  Kanonidis,  &  Lourida,  2010).  This  can  give  an
in-depth understanding of the medical condition and hence
improves the disease diagnosis and personalized medicine
(Louridas & Lourida, 2012). In fact, the power of systems bio-
logy is based on the concept that although the clinical pheno-
type of a molecular disturbance is not obvious, the conse-
quent compensatory adaptation due to this disturbance will
be reflected in the transcriptome, proteome or metabolome
(Kuster et al., 2011).
4.1 Disciplines of systems biology
Systems biology combines group of (-omics) disci-
plines, particularly the main major omics such as genomics,
transcriptomics,  proteomics  and  metabolomics.  While
genomics focuses on the genome sequencing, transcriptomics
studies the transcription and expression of gene sets using
gene expression microarrays or RNA sequencing (Cappola &
Margulies, 2011; Piran, Liu, Morales, & Hershberger, 2012).
These expressions will yield proteins, which can be measured
by mass spectroscopy (MS). The biochemical modifications
to proteins can reflect a state of specific medical conditions.
Lastly, the metabolic process in cells and organs ends with
the production of metabolites, which perform the metabolome
or  metabolic  profile.  Metabolomics  aim  to  discover  and
measure the changes in metabolome. Each one of the systems
biology  disciplines  has  been  found  to  give  fingerprints  of
prognostic  value  in  diagnosing  diseases.  However,  meta-
bolomics is the ultimate screen that reflects other omics in
addition to environmental factors. The use of systems bio-
logy disciplines to diagnose complicated medical conditions
such as cancer, cardiovascular diseases and liver disease, has
the advantage of being less invasive and fast. Figure 1 shows
how the systems biology disciplines help in the understand-
ing of the pathophysiology of diseases and the pathways
behind specific phenotypic manifestation of the disease. The
figure shows that metabolomics is the ultimate internal picture
of disease phenotype, which can reflect the perturbation in
other omics fields which precede metabolomics.
5. Metabolomics in Disease Diagnosis
Metabolomics  (or  metabonomics  in  some  of  the
literatures) deals with the identification and quantification of
small molecular compounds (metabolites) in the metabolic
profile (metabolome) of the living organism (Corona, Rizzolio,
Giordano, & Toffoli, 2012; Louridas & Lourida, 2012). The
metabolome of each organism is highly affected either by
internal or external environmental factors. The variations in
the metabolome usually are associated with disease pheno-
type,  specific  nutrition  exposure  and  drug  response  or
toxicity. The pattern of this variation can be considered as the
metabolic fingerprint or surrogate biomarkers of the clinical
condition or disease under investigation. Different medical
conditions  can  have  their  distinct  metabolic  finger  print
(metabotype).The metabotype is a group of certain metabo-
lites that, either by their presence or absence, increased or
decreased concentration, are distinctive for a specific clinical
status  or  disease  (Semmar,  2012).  This  metabotype  gives
better understanding of the pathways that lead to changes
in the metabolites due to disease, drug and/or environmental
effects (Harrigan et al., 2008). A metabotype does not only
reflect the variation in genetics, transcriptomics and proteo-
mics, which might be associated with the condition, but also
the environmental factors interfering with them (Gutiu et al.,
2010). In the diagnosis of some diseases, it is difficult to have
definite diagnosis without further invasive procedures such
as cancer and cardiovascular diseases (Corona et al., 2012;
Shah,  Kraus,  &  Newgard,  2012).  Therefore,  identifying  a
metabotype associated with the disease is a non-invasive tool
for disease diagnosis. Similarly, metabolomics can be used to
identify a metabotype which can predict body response to
drugs and xenobiotics. This will help to monitor, guide and
evaluate the current therapy, and help to find new drug
target.The metabolomics analysis involves analyzing biolo-
gical samples such as blood, urine, cerebrospinal fluids (CSF),
breath, seminal fluids and tissues using instruments such as
nuclear magnetic resonance (NMR) spectroscopy and MS
(Clayton  et  al.,  2006).  The  blood  and  urine  samples  are
usually considered stable and less invasive biological samples
Figure 1. The role of systems’ biology disciplines (omics) in disease
diagnosis,  where  metabolomics  represents  the  ultimate
biomarkers level for detection of the disease before the
phenotypic manifestations (adapted and modified from
(Piran et al., 2012)).
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where  urine  is  less  invasive  and  easy  to  get  in  abundance
(Decramer et al., 2008; Down, 2010; Griffiths, 2008; Vaid-
yanathan, Harrigan, & Goodacre, 2005; Want et al., 2010).
Therefore, the researchers prefer plasma, serum and urine in
metabolomics studies.
Metabolomics  studies  have  been  able  to  identify
metabotypes of diseases such as liver disease, diabetes,
asthma, COPD, cancer and metabolic disorders using differ-
ent biological fluid samples of patients and healthy controls
(Hocquette, 2005; Hunt & John, 2007). The discriminating
metabotypes usually have high specificity and sensitivity.
Table 1 presents examples of metabolomics studies to diag-
nose  diseases.  These  metabolomics  studies  are  part  of  a
continually growing body reflecting the preeminent role of
metabolomics  in  diseases  diagnosis  and  the  pathogenic
understanding of diseases and variable medical conditions.
5.1 Metabolomics in the prediction of substance exposure
Some of the metabolomics studies aimed to investi-
gate metabolic changes consequent to the exposure to envi-
ronmental  factors  or  toxins,  such  as  smoking  and  other
harmful substances. In an approach to explore the effects of
smoking and smoking cessation, researchers had used meta-
bolomics techniques to quantify 140 metabolites in fasting
serum of three groups, namely current smokers, non-smokers
and quitters (who have quitted during the follow up period of
the study) in a longitudinal analysis (Xu et al., 2013). They
had found that 21 smoking related metabolites were signifi-
cantly  different  from  current  smokers  and  non-smokers.
Interestingly,  the  study  discovered  that  19  out  of  the  21
metabolites were reversible in quitters. In study which aimed
to  test  the  systemic  toxicity  of  welding  fumes,  Wei  and
colleagues used liquid and gas chromatography-MS to inves-
tigate the plasma metabolome of boilermakers pre-welding
and post-welding fumes exposure in two stage-study (Wei
et al., 2013). The first stage was conducted in 2011 on 11
boilermakers. The second stage was conducted in 2012 on 8
boilermakers, where five of them participated in first stage in
addition to three new recruited boilermakers. The results
showed that the high exposure to high metal welding fumes
causes decrease in the level of unsaturated fatty acids.
5.2 Using 1H-NMR spectroscopy in metabolomics
The proton nuclear magnetic resonance 1H-NMR is
one of the main analytical tools that is being widely used
in metabolomics, in addition to MS and fourier transform
infrared spectroscopy (FT-IR) (Basanta et al., 2012; Lloyd
et al., 2011; Schicho et al., 2012). It is being widely used in
metabolomics because it has the advantage of quickly reveal-
ing the metabolic profile of the biological sample depending
on the magnetic properties of the widely spread hydrogen
atom  in  the  chemical  structure  of  the  metabolites  (Dunn,
Bailey, & Johnson, 2005). The concept that 1H-NMR analysis
relies  on  is  that  every  compound  or  metabolite  contains
hydrogen atoms in different chemical structure forms will give
specific and different peaks in the NMR spectra when the
compound enters the magnetic field. These peaks are charac-
teristic for each compound. Although 1H-NMR has lower
sensitivity when compared to MS (Silva Elipe, 2003), the
1H-NMR analysis is less complex as the sample does not need
prior derivatization, extraction and separation as required by
MS (Clayton et al., 2006). In addition, 1H-NMR act as an
independent  instrument  compared  to  MS  which  requires
separation   instrument  like  GC  or  LC  (Dunn  et  al.,  2005).
Table 1. Examples of metabolomics studies to diagnose diseases.
             Study Disease Analytical Specimen                                        Findings
Method
(Ibrahim et al., 2011) Asthma GC-MS Breath Development of a discriminatory model which
classifies asthma patients with accuracy of 86%
(Basanta et al., 2012) COPD GC-MS Breath Development of a discriminatory model which
discriminate COPD patients from their healthy
controls with 85% sensitivity and 50% specificity
(Schicho et al., 2012) IBD 1HNMR Serum, Plasma Characterization of 44 serum, 37 plasma and 71
and Urine urine metabolites to differentiate between diseased
and non-diseased individuals
(Motsinger-Reif Alzheimer’s LC-ECA CSF Identified biomarkers which discriminate
  et al., 2013) with Dementia GC-TOF MS Alzheimer’s patients from their healthy controls
(Lewitt et al., 2013) Parkinson’s UPLC and CSF Identification of 19 compounds which were able to
disease (PD) GC- MS discriminate PD patients from similar age healthy
controls with a false discovery level of 20%
GC-TOF MS: gas chromatography-time of flight mass spectroscopy, CSF: cerebrospinal fluid, UPLC: ultra performance liquid
chromatography, IBD: Inflammatory bowel disease, COPD: Chronic obstructive pulmonary disease, LC-ECA: liquid chromatog-
raphy-electrochemical coulometric array.
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In NMR metabolomics, plasma and urine samples will be
mixed with buffer before analyzing them in the NMR machine.
Chemometrics software will be used to process the obtained
NMR  spectrum  to  elucidate  and  identify  the  chemical
structure of the metabolites in the samples. Metabolites web-
based  and  software  databases  can  be  used  to  assist  the
identification.  This  will  help  to  assign  the  metabotype  of
interest. The 1H-NMR can analyze many samples per day and
the samples can be stored and reused for further analysis
(Nicholson & Lindon, 2008; Shulaev, 2006). Therefore, the
1H-NMR  is  considered  cheap  and  non-destructive  when
compared to MS. Figure 2 illustrates a Google scholar based
literature search for publications containing (metabolomics
and NMR) and (metabonomics and NMR). The search showed
an increase in the number of publications from a total of 67
articles in year 2000 to 5870 articles in 2014. This reflects
the great interest in using NMR in metabolomics studies.
5.3 Using metabolomics to investigate alcohol consumption
There are metabolomics studies that investigated the
effects of alcohol consumption by analyzing the biological
samples of animals on alcohol containing diets. Furthermore,
researchers explored this in humans as well.
5.3.1 Using metabolomics to investigate alcohol consumption
in animal models
Some metabolomics studies used the metabolomics
approach to study the pathogenesis of alcohol consumption
in  animal  models.  Most  of  these  studies  were  oriented  by
expected consequences of alcohol’s detrimental effect on
liver (Bradford et al., 2008; Fernando et al., 2010; Loftus et
al., 2011). Bradford and colleagues used 1H-NMR and MS
metabolomics techniques to evaluate the metabolic profile of
urine and liver extract samples of mice with alcohol induced
liver injury (Bradford et al., 2008). The mice were divided into
two groups, one was fed with iso-caloric (control group) and
the other group was fed with alcohol containing liquid diet
(alcohol group) of which the steatohepatitis was confirmed
by 5-fold increase of serum ALT, 6-fold increase in liver injury
score and the increase of lipid peroxidation in the liver. The
1H-NMR principal component analysis of both urine and liver
extracts  showed  obvious  discrimination  between  the  two
groups. For instance, the lactate was high in both liver and
urine of those mice in the alcohol group. N-oleoylethanola-
mine metabolite was found to be elevated as well. Both lactate
and N-oleoylethanolamine indicated hypoxic injury of the
liver. Tyrosine was found to be elevated which might reflect
an alteration in metabolism due to alcohol. Moreover, there
was  a  decrease  in  the  excretion  of  taurine  (glutathione
metabolite) in the urine of the alcohol group. Additionally,
there was an increase in prostacycline inhibitor 7,10,13,16-
docosatetraenoic  acid  which  is  vital  in  the  regulation  of
platelets  formation.  Similarly,  Loftus  and  colleagues  used
LC-MS metabolomics analysis to explore the metabolomics
changes in non-polar metabolites of rodents’ livers due to
alcohol consumption (Loftus et al., 2011). The study was
conducted on rats and mice fed with intragastric alcohol feed-
ing model.The analysis of liver derived samples revealed a
significant increase of fatty acyls, fatty acid ethyl esters, in
addition to octadecatrienoic acid and eicosapentaenoic acid
metabolites.  In  another  study,  Fernando  and  colleagues
extracted  lipids  from  the  plasma  and  liver  of  rats  fed  with
alcohol diets and their controls (Fernando et al., 2010). From
both 1H-NMR and 31P-NMR analysis, they concluded that
a significant alteration in lipid metabolism was induced by
alcohol consumption. To the best of our literature review
we have found that most of the metabolomics studies which
assessed alcohol consumption in animal models, focused on
specific organ injury, particularly liver injury. None of these
studies  aimed  to  find  the  biomarkers  of  chronic  use  of
alcohol or AD.
5.4.2 Using metabolomics to investigate alcohol consump-
tion in humans
There are few metabolomics studies that studied the
effect  of  alcohol  consumption  on  human  metabolome.
Jaremek and colleagues investigated the effects of alcohol
consumption on human serum metabolome (Jaremek et al.,
2013). Researchers compared the serum metabolome of two
Figure 2.  Literature search at Google scholar for publications of (metabolomics + NMR) and (Metabonomics + NMR).
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groups, light drinkers (LD) and moderate to heavy drinkers
(MHD). The results showed that the concentration 40 identi-
fied metabolites in males and 18 in females differed signifi-
cantly  between  the  two  groups.  Out  of  these  metabolites,
10 in males and 5 in females were specific metabolites to dis-
criminate LD from MHD. The investigators concluded that
alcohol consumption mostly affect metabolic profile classes
of diacylphosphatidylcholines, lysophosphatidylcholines,
ether lipids and sphingolipids. These results indicated that
the  stimulatory  effect  of  alcohol  consumption  on  acid
sphingo-myelinase (ASM) activity causes the accumulation
of  ceramide  and decrease  of  sphingomyelins.  However,  the
study did not explore the metabolic variation associated with
chronic use of alcohol or AD. Additionally, it did not investi-
gate urine metabolomics which is non-invasive compared to
blood.  In  another  study,  the  researchers  used  1H-NMR
metabolomics technique to find serum metabolic fingerprint
that discriminate alcoholic liver cirrhosis from hepatitis B
virus liver cirrhosis (Qi et al., 2012). The investigators found
that  five  metabolites  could  distinguish  between  the  two
different  types  of  cirrhosis.  However,  the  study  did  not
explore urine metabolic profile and did not look for metabolic
fingerprint of chronic use of alcohol. Recently, we evaluated
using1H-NMR metabolomics to identify novel biomarkers of
AD in plasma and urine (Mostafa et al., 2016; Mostafa et al.,
2017). We analyzed plasma and urine samples of three groups
from East Asians population; AD patients, social drinkers
and naïve control. The analysis showed that 1H-NMR is able
to  discriminate  between  AD  subjects  and  both  naïve  and
social drinkers subjects with high accuracies. In plasma, the
accuracy of the identified biomarkers was 94.2%.  In urine,
the accuracy of the identified biomarkers was 92%. These
findings showed that 1H-NMR metabolo-mics can be a pre-
eminent approach to accurately diagnose AD. It is necessary
to validate these findings in other populations. Table 2 shows
a summary of metabolomics studies conducted on alcohol
consumption and AD.
6. Conclusions
AD is a disease which burdens patients and society,
therefore, the early diagnosis of AD is imperative to start the
optimum treatment and to prevent the detrimental effects of
chronic consumption of alcohol. Indeed, this detection might
encourage AD individuals to seek treatment for their illness.
Besides, it is substantial for the society to detect individuals
suffering from AD to address them with awareness programs
on the harmful effects of chronic alcohol consumption. This
will  not  only  have  a  positive  impact  on  AD  individuals
themselves but also on their families and the society. As the
optimum treatment of diseases requires precise diagnosis,
finding accurate method to diagnose AD is crucial for the
treatment. The benefits of the rapid, non-selective and non-
destructive  analytical  tool  such  as  1H-NMR  has  distinctly
increased  its  use  in  metabolomics  recently.  Applying  this
technique  in  AD  diagnosis  can  provide  fast  and  reliable
precise diagnosis.
Table 2. Examples of metabolomics studies to study alcohol consumption.
             Study Class Analytical Specimen                                  Main Findings
Method
(Bradford et al., 2008) Mice 1H-NMR Liver extract The analysis showed significantdiscrimination
and MS and urine  between the control and alcohol groups.
(Fernando et al., 2010) Rats 1H-NMR and Plasma and A significant alteration in lipid metabolism
31P-NMR liver samples  was induced by alcohol consumption.
(Loftus et al., 2011) Rats and LC-MS Liver samples The study revealed a significant increase of
mice fatty acyls, fatty acid ethyl esters, in addition to
octadecatrienoic acid and eicosapentaenoic acid
metabolites.
(Qi et al., 2012) Human 1H-NMR Serum Five metabolites could distinguish between
alcoholic liver cirrhosis and hepatitis B virus
liver cirrhosis.
(Jaremek et al., 2013) Human LC-MS Serum Ten metabolites in males and 5 in females
were specific metabolites to discriminate light
drinkers from moderate to high drinkers.
(Mostafa et al., 2016) Human 1H-NMR Urine Six biomarkers discriminated between alcohol
dependence from social drinkers and alcohol-naive.
(Mostafa et al., 2017) Human 1H-NMR Plasma Two biomarkers could differentiate between
individuals with AD from social drinkers and
alcohol-naive.
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